Press Release

The Global Erectile Dysfunction Drugs Market is expected to Grow at a CAGR of 9.3% during the Forecast Period 2018–2024 to Aggregate $2,077.9 million by 2024

May, 2018

" "

The increase in ED cases has led to the rise in demand for ED drugs and the market is expected to witness an increase in sales.

Bangalore, India, April, 2018: The recently published Infoholic Research study “Erectile Dysfunction Drugs Market – Global Drivers, Restraints, Opportunities, Trends, and Forecasts up to 2024”, estimates the market is declining and is projected to see negligible growth during the forecast period. The market is primarily triggered by commercial advertisements and TV campaigns that have a huge customer following. Such measures will make individuals gain proper awareness about the products available at their disposal. This market is being consistently advertised on media with extensively targeted male-oriented indications. According to studies, viewers of national news programs and other media channels were exposed to a broad category of advertising during 40% to 60% of broadcasts with a steady increasing exposure since 2010.

Factors such as ageing, progressive health condition, hypertension, alcohol consumption, secondary medical conditions such as diabetes depression, cardiovascular, and another urological disorder have a serious effect on the male sexual health. This condition is mostly age-related and about 50% of men aged between 40 years to 70 years stand the risk of suffering from this condition. According to a research study, men aged between 40 years and 75 years who are affected with ED have secondary medical conditions such as diabetes and other chronic issues. The increase in ED cases has led to the rise in demand for ED drugs and the market is expected to witness an increase in sales. According to Infoholic Research, the Global Erectile Dysfunction Drugs Market is expected to grow at a CAGR of -9.3% during the forecast period 2018–2024 to reach an aggregate of $2 billion by 2024.

Download Sample @

The market is analyzed based on three segments, namely product types, end-users, and regions. The regions covered in the report are North America, Europe, Asia Pacific, and Rest of the World (ROW). In North America, the US and Canada are set to be the leading countries owing to the highest number of Erectile Dysfunction cases in 2017. This region dominates the overall presence of ED drugs and has the most number of ED drugs available. It has the highest percentage of elderly population with many individuals suffering from chronic diseases such as CVD, diabetes, obesity, high blood pressure, and other urology related factors. This has attracted most market players to sustain and grow over a period of time and maintain their product presence in this domain.

Europe is set to be the second leading region and held more than 28% of the market share in 2016. The UK is one of the countries in Europe with high prevalence of ED, followed by France and Germany. The burden of ED in Europe is significant and most men have an elevated risk of this condition. According to research based studies, most of the article findings have confirmed the positive prospect of ED in men aged above 40 years. Factors such as aging population, increase incidence of chronic diseases such as obesity, diabetes, neurological disorders, and smoking have caused significant impact on men’s sexual condition.

The advancement in drug development process and the anticipated launch of new (generics) products is expected to increase the sales in developed countries. In Asia Pacific, India and China are the most attractive countries for the players and they hold tremendous business opportunities. ROW is set to be an emerging market in the next 5–6 years.

Buy Complete Report @

“Men with erectile dysfunction have difficulty leading a fulfilling sex life. Ongoing erection issues often affects one’s self-esteem and the ability to perform sex with their partner. There are a wide variety of drugs available to treat ED that are effective in men even with diabetes. However, ED drugs may or may not work as best treatment and many individuals seek other alternatives or substitutes to reverse their condition. The revolution in the treatment of ED has given rise to new and alternative developments that are non-invasive, need no surgery or oral therapy. Stem cell therapy, topical gel, and shockwave therapy will play a substantial role in repairing the vascular damage in future. Further, new products with safety and efficiency pharmacology approach and cheap generics will drive the market and help men overcome ED.” - Mohammed Azhar, Senior Research Analyst (Research – Healthcare) at Infoholic Research.

About Infoholic Research

Infoholic Research is a global market research and consulting organization providing strategic and high-level market intelligence in emerging and niche technologies. Founded in 2014, we are headquartered in India with an office in the US and with consultants working across the globe. Our market analysis powered by rigorous methodology and quality metrics provides information and forecast across all the emerging markets, technologies and business models. We aim at delivering high-quality results to our clients providing them with in-depth industry insights to identify new business opportunities and nurture their business strategies. For more information, please visit


Mr. Karthick Subramani

Infoholic Research LLP

Marketing & Communication